Primary Sclerosing Cholangitis: The Role of Endoscopic Therapy

ABSTRACT

Primary sclerosing cholangitis is characterized by progressive fibrosing inflammation of the bile ducts leading to their obliteration, resulting in cholestasis, and finally, cirrhosis of the liver. The majority of patients with advanced disease with time develop dominant stenoses of major bile ducts. Such dominant stenoses may be recognized by magnetic resonance cholangiopancreatography with good specificity and sensitivity, but for definite diagnosis and especially for therapeutic decisions, endoscopic retrograde cholangiography still represents the gold standard. Ursodeoxycholic acid treatment does not prevent the development of such stenoses. Endoscopic measures allow the opening of short-and long-segment stenoses of the common bile duct. Short- but not long-segment stenoses of the hepatic ducts near to the bifurcation also may be treated endoscopically. Repeated balloon dilatations over years appear to be the treatment of choice. In patients treated by early endoscopic dilatation of dominant stenoses, survival may be significantly improved compared with the predicted survival.

KEYWORDS

Endoscopic therapy - dominant stenosis - balloon dilatation

REFERENCES

• 1 Chapman R W, Arborgh B A, Rhodes J M et al.. Primary sclerosing cholangitis-a review of its clinical features, cholangiography and hepatic histology.  Gut. 1980;  21 870-877
• 2 Wiesner R H, Grambsch P M, Dickson E R et al.. Natural history, prognostic factors, and survival analysis.  Hepatology. 1989;  10 430-436
• 3 Farrant J M, Hayllar K M, Wilkinson M L et al.. Natural history and prognostic variables in primary sclerosing cholangitis.  Gastroenterology. 1991;  100 1710-1717
• 4 Broomé U, Olson R, Lööf L et al.. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis.  Gut. 1996;  38 610-615
• 5 Fulcher A S, Turner M A, Franklin K J et al.. Primary sclerosing cholangitis: evaluation with MR cholangiography-a case control study.  Radiology. 2000;  215 71-80
• 6 Angulo P, Pearce D H, Johnson C D et al.. Magnetic resonance cholangiography in patients with biliary disease: its role in primary sclerosing cholangitis.  J Hepatol. 2000;  33 520-527
• 7 Textor H J, Flacke S, Pauleit D et al.. Three-dimensional magnetic resonance cholangiopancreaticography with respiratory triggering in the diagnosis of primary sclerosing cholangitis: comparison with endoscopic retrograde cholangiography.  Endoscopy. 2002;  34 984-990
• 8 Stiehl A, Rudolph G, Sauer P et al.. Efficacy of ursodeoxycholic acid and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study.  J Hepatol. 1997;  26 560-566
• 9 Stiehl A, Rudolph G, Klöters-Plachky P et al.. Development of bile duct stenoses in patients with primary sclerosing cholangitis treated with ursodeoxycholic acid. Outcome after endoscopic treatment.  J Hepatol. 2002;  36 151-156
• 10 Grijm R, Huibregtse K, Bartelsman J et al.. Therapeutic investigations in primary sclerosing cholangitis.  Dig Dis Sci. 1986;  31 792-798
• 11 Johnson G K, Geenen J E, Venu R P, Hogan W J. Endoscopic treatment of biliary duct strictures in sclerosing cholangitis: Follow up assessment of a new therapeutic approach.  Gastrointest Endosc. 1987;  33 9-12
• 12 Cotton P B, Nickl N. Endoscopic and radiologic approaches to therapy in primary sclerosing cholangitis.  Semin Liver Dis. 1991;  11 40-48
• 13 Craig P I, Hatfield A RW. Endoscopic therapy in primary sclerosing cholangitis.  Eur J Gastroenterol Hepatol. 1992;  4 284-287
• 14 Gaing A A, Geders J M, Cohen S A, Siegel J H. Endoscopic management of primary sclerosing cholangitis: review, and report of an open series.  Am J Gastroenterol. 1993;  88 2000-2008
• 15 Lee J G, Schutz S M, England R E, Leung J W, Cotton P B. Endoscopic therapy of sclerosing cholangitis.  Hepatology. 1995;  21 661-667
• 16 van Milligen de Wit A WM, van Bracht J, Rauws E AJ et al.. Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis.  Gastrointest Endosc. 1996;  44 293-299
• 17 Wagner S, Gebel M, Meier P et al.. Endoscopic management of biliary tract strictures in primary sclerosing cholangitis.  Endoscopy. 1996;  28 546-551
• 18 Kaya M, Angulo P, Peterson B T. Balloon dilatation compared to stenting of dominant strictures in primary sclerosing cholangitis.  Am J Gastroenterol. 2001;  96 1059-1066
• 19 Baluyut A R, Sherman S, Leman G A, Hoen H, Chalasani N. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis.  Gastrointest Endosc. 2001;  53 308-312
• 20 Olsson R, Björnsson E, Bäckman L et al.. Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers.  J Hepatol. 1998;  28 426-432
• 21 Pohl J, Ring A, Stremmel W, Stiehl A. The role of dominant stenoses in bacterial infections of bile ducts in PSC.  Eur J Gastroenterol Hepatol. 2006;  18 69-74
• 22 Hammel P, Couvelard A, O’Toole D et al.. Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common duct.  N Engl J Med. 2001;  344 418-423
• 23 May G R, Bender C E, LaRusso N J, Wiesner R H. Nonoperative dilatation of dominant strictures in primary sclerosing cholangitis.  AJR Am J Roentgenol. 1985;  145 1061-1068
• 24 Färkkilä M, Karvonen A L, Nurmi H et al.. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.  Hepatology. 2004;  40 1379-1386
• 25 Hutcrantz R, Olsson R, Danielsson A et al.. A 3 year prospective study on serum tumor markers used for detecting cholangiocarcinoma in patients with primary sclerosing cholangitis.  J Hepatol. 1999;  30 660-673
• 26 Ponsioen C Y, Vrouenraets S M, van Milligen de Wit A W et al.. Value of brush cytology for dominant strictures in primary sclerosing cholangitis.  Endoscopy. 1999;  31 305-309
• 27 Keiding S, Hansen S B, Rasmussen H H et al.. Detection of cholangiocarcinoma in primary sclerosing cholangitis by positron emission tomography.  Hepatology. 1998;  28 700-706
• 28 Kluge R, Schmidt F, Caca K et al.. Positron emission tomography with (18F)fluoro-2-deoxy-D-glucose for diagnosis and staging of bile duct cancer.  Hepatology. 2001;  33 1029-1035
• 29 Beuers U, Spengler U, Kruis W et al.. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo controlled trial.  Hepatology. 1992;  16 707-714
• 30 Stiehl A, Walker S, Stiehl L et al.. Effects of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3 year pilot study with a placebo- controlled study period.  J Hepatol. 1994;  20 57-64
• 31 Mitchell S A, Bansi D, Hunt N et al.. A preliminary trial of high dose ursodeoxycholic acid in primary sclerosing cholangitis.  Gastroenterology. 2001;  121 900-907
• 32 Lindor KD and the Mayo PSC/UDCA study group . Ursodiol for the treatment of primary sclerosing cholangitis.  N Engl J Med. 1997;  336 691-695
• 33 Harnois D M, Angulo P, Jorgensen R A, LaRusso N F, Lindor K D. High-dose ursodeoxycholic acid as therapy for patients with primary sclerosing cholangitis.  Am J Gastroenterol. 2001;  96 1558-1562